Advertisement
Australia markets open in 8 hours 43 minutes
  • ALL ORDS

    7,996.50
    -10.60 (-0.13%)
     
  • AUD/USD

    0.6516
    -0.0010 (-0.16%)
     
  • ASX 200

    7,735.80
    -9.80 (-0.13%)
     
  • OIL

    80.23
    +0.26 (+0.33%)
     
  • GOLD

    2,099.50
    +3.80 (+0.18%)
     
  • Bitcoin AUD

    100,052.33
    +4,360.40 (+4.56%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study

(Adds details throughout)

Nov 27 (Reuters) -

Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study.

Still, the company said it was actively exploring future development of the drug candidate, XEN1101, as a treatment for MDD.

Xenon said the study data was compelling, building upon the ongoing late-stage study for the use of XEN1101 in treating epilepsy. (Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)